Sustained low functional impairment in axial spondyloarthritis (axSpA): which are the primary outcomes that should be targeted to achieve this?

Table 3 Predictors of BASFI score at 18 months in multivariable analyses

Model	Parameter	B^a	95% CI	P-value
Model 1 (N = 180)	Baseline BASFI	0.30	0.19, 0.41	< 0.001
	Low BASDAI at M6 and M12 vs persistent BASDAI ≥ 3	− 2.45	− 3.35, − 1.55	< 0.001
	Low BASDAI at M6 or M12 vs persistent BASDAI ≥ 3	− 2.14	− 2.88, − 1.41	< 0.001
	ASDAS-ID at M6 and M12 vs persistent ASDAS ≥ 1.3	− 1.10	− 2.15, − 0.05	0.041
	ASDAS-ID at M6 or M12 vs persistent ASDAS ≥ 1.3	− 0.70	− 1.62, 0.22	0.136
	Age, years	0.04	0.02, 0.07	0.001
	Gender, male vs female	0.35	− 0.22, 0.92	0.228
	Baseline Disease Duration, years	− 0.02	− 0.05, 0.01	0.121
Model 2 (N = 180)	Baseline BASFI	0.29	0.18, 0.40	< 0.001
	Low BASDAI at M6 and M12 vs persistent BASDAI ≥ 3	− 2.22	− 3.04, − 1.40	< 0.001
	Low BASDAI at M6 or M12 vs persistent BASDAI ≥ 3	− 1.91	− 2.67, − 1.15	< 0.001
	ASDAS-LDA at M6 and M12 vs persistent ASDAS ≥ 2.1	− 1.50	− 2.36, − 0.64	0.001
	ASDAS-LDA at M6 or M12 vs persistent ASDAS ≥ 2.1	− 0.44	− 1.12, 0.25	0.213
	Age, years	0.04	0.02, 0.07	< 0.001
	Gender, male vs female	0.39	− 0.17, 0.96	0.172
	Baseline disease duration, years	− 0.02	− 0.05, 0.01	0.109

BASFI Bath Ankylosing Spondylitis Functional Index; CI confidence interval; M month; BASDAI Bath Ankylosing Spondylitis Disease Activity Index; ASDAS Ankylosing Spondylitis Disease Activity Score; ID inactive disease; LDA low disease activity
Bold P-values denote statistical significance
^aPositive beta coefficient (B) indicates increased BASFI score at 18 months

ISSN: 1478-6362